Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

PURPOSE: This phase I, first in human, first in class clinical study aimed at evaluating the safety, tolerability and efficacy of treatment with genetically modified mesenchymal stromal cells (MSC) in combination with ganciclovir (GCV). MSC_apceth_101 are genetically modified autologous MSCs used as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: von Einem, Jobst C., Peter, Sylvia, Günther, Christine, Volk, Hans-Dieter, Grütz, Gerald, Salat, Christoph, Stoetzer, Oliver, Nelson, Peter J., Michl, Marlies, Modest, Dominik P., Holch, Julian W., Angele, Martin, Bruns, Christiane, Niess, Hanno, Heinemann, Volker
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655186/
https://ncbi.nlm.nih.gov/pubmed/29113291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20964
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados